The Office of the U.S. Trade Representative does not have imminent plans to escalate a row over Mexico’s biotechnology policies to a dispute under the U.S.-Mexico-Canada Agreement, an agency spokesperson said this week after a preliminary, mandated consultation period elapsed.



